Prof. Baytan ist ein Arzt, der 1992 seinen Abschluss an der Medizinischen Fakultät der Universität Ankara machte und Facharzt für Medizin an der Medizinischen Fakultät der Universität Uludağ, Abteilung für Kinderkrankheiten, wurde. Er ist erfahren in der Diagnose und Behandlung von Krebs im Kindesalter, Leukämie, Anämie und anderen Krankheiten. Er hat 15 Artikel in internationalen Fachzeitschriften veröffentlicht, 9 Volltexte präsentiert und auf internationalen wissenschaftlichen Tagungen veröffentlicht, 3 Bücher/Buchkapitel geschrieben und 8 Artikel in lokalen Fachzeitschriften veröffentlicht.
Mehr lesenProf. Baytan ist ein Arzt, der 1992 seinen Abschluss an der Medizinischen Fakultät der Universität Ankara machte und Facharzt für Medizin an der Medizinischen Fakultät der Universität Uludağ, Abteilung für Kinderkrankheiten, wurde. Er ist erfahren in der Diagnose und Behandlung von Krebs im Kindesalter, Leukämie, Anämie und anderen Krankheiten. Er hat 15 Artikel in internationalen Fachzeitschriften veröffentlicht, 9 Volltexte präsentiert und auf internationalen wissenschaftlichen Tagungen veröffentlicht, 3 Bücher/Buchkapitel geschrieben und 8 Artikel in lokalen Fachzeitschriften veröffentlicht.
Dr. Özer Akgül ist ein erfahrener türkischer Radioonkologe mit einem MD von der Uludag University Medicine School (Bursa) und einer Facharztausbildung am Ege University Hospital. Er ist in der Lage, onkologische Trends zu überwachen, gesetzte Ziele zu erreichen, Marktanforderungen zu verstehen und Strategien zu entwickeln. Zu seinen Interessengebieten gehören Brustkrebs, Lungenkrebs, Prostatakrebs, Rektumkrebs, Kopf- und Halskrebs, Gebärmutterhalskrebs, Magenkrebs und Hirntumore. Er besuchte Kurse und forschte in den Bereichen Nanobiotechnologie, Genetik, medizinische Onkologie, gynäkologische Krebserkrankungen, Bioinformatik, bionanotechnologische Methoden, klinische Radiobiologie, medizinische Radiophysik, evidenzbasierte Radioonkologie, bildgeführte Strahlentherapie und Chemotherapie, Varian Advanced Techniques Clinical School, Stereotactic Strahlentherapie und Varian Advanced Imaging (IGRT). Er ist Mitglied von TROD, Turkish Medical Association, MOKAD und ESTRO.
Mehr lesenDr. Özer Akgül ist ein erfahrener türkischer Radioonkologe mit einem MD von der Uludag University Medicine School (Bursa) und einer Facharztausbildung am Ege University Hospital. Er ist in der Lage, onkologische Trends zu überwachen, gesetzte Ziele zu erreichen, Marktanforderungen zu verstehen und Strategien zu entwickeln. Zu seinen Interessengebieten gehören Brustkrebs, Lungenkrebs, Prostatakrebs, Rektumkrebs, Kopf- und Halskrebs, Gebärmutterhalskrebs, Magenkrebs und Hirntumore. Er besuchte Kurse und forschte in den Bereichen Nanobiotechnologie, Genetik, medizinische Onkologie, gynäkologische Krebserkrankungen, Bioinformatik, bionanotechnologische Methoden, klinische Radiobiologie, medizinische Radiophysik, evidenzbasierte Radioonkologie, bildgeführte Strahlentherapie und Chemotherapie, Varian Advanced Techniques Clinical School, Stereotactic Strahlentherapie und Varian Advanced Imaging (IGRT). Er ist Mitglied von TROD, Turkish Medical Association, MOKAD und ESTRO.
Prof. Songul Serefhanoglu ist seit 2019 Hämatologe am ISU Medical Park und seit 2019 Direktor und Präsident der Abteilung für Erwachsenenhämatologie des Sisli Memorial Hospital, Istanbul. Er absolvierte seine medizinische Ausbildung an der Firat University, Elazig/Türkei (1994-2000). ), Innere Medizin von der Inonu University, Malatya/Türkei (2001-2005) und Hämatologie von der Hacettepe University, Ankara/Türkei (2006-2009). Er war an der Transplantation peripherer hämatopoetischer Stammzellen beteiligt, mit durchschnittlich 100-120/Jahr.
Mehr lesenProf. Songul Serefhanoglu ist seit 2019 Hämatologe am ISU Medical Park und seit 2019 Direktor und Präsident der Abteilung für Erwachsenenhämatologie des Sisli Memorial Hospital, Istanbul. Er absolvierte seine medizinische Ausbildung an der Firat University, Elazig/Türkei (1994-2000). ), Innere Medizin von der Inonu University, Malatya/Türkei (2001-2005) und Hämatologie von der Hacettepe University, Ankara/Türkei (2006-2009). Er war an der Transplantation peripherer hämatopoetischer Stammzellen beteiligt, mit durchschnittlich 100-120/Jahr.
Prof. Dr. Osman İLHAN graduated from Ankara University Faculty of Medicine in 1978. After completing his internal medicine residency at the same faculty in 1982, he served as a senior resident at the GATA Hematology Clinic during his military service. After completing his mandatory service at SSK Ulus Hospital, he returned to Ankara University Faculty of Medicine for a subspecialty. In 1990, he became an associate professor of hematology. He worked in Genoa, Italy to increase his knowledge and experience in leukemia. He was part of the team that performed the first bone marrow stem cell transplant in Turkey. In 1996, he went to the MD Anderson Cancer Center in the USA to work on "Stem Cell Mobilization, Cryopreservation, and Transplantation." In 1996, he became a professor of hematology. In 1999, he was elected as the regional president of ESFH (European Society for Hemapheresis). Dr. İlhan, who was the founder and president of the Hemapheresis Society in 2000, joined the World Apheresis Association (WAA) in 2001. He became the President of the Turkish Hematology Association in October 2001. Dr. İlhan, who is an active member of the European Hematology Association (EHA), was a member of the accreditation committee (ECAH) for education. He played a role in the accreditation of Turkish hematologists in CME credits by participating in the accreditation of congresses and courses held in Turkey as a Provider Status. He served as the founding president of the Cellular Therapy and Regenerative Medicine Association established in 2008. He became the founding president of the Geriatric Hematology Association in 2011. He is the Honorary President of the World Apheresis Congress (WAA) held in 2012. Dr. İlhan, who previously served on drug licensing and ethics committees at the Ministry of Health, has also served as the Chairman of the Photopheresis-Apheresis Commission and the Scientific Committee for Bone Marrow Transplantation, as well as the Chairman of the National Organ Tissue Cell Coordination Board, the Scientific Board of Cord Blood, and the Stem Cell Research Board. He is the founding president of the STEM CELL FOUNDATION and has played an important role in the establishment of TURKOK (Turkish Stem Cell Donor Bank). Dr. İlhan has over 300 publications in journals registered in PubMed and more than 5000 citations. He holds the Platinum CME certificate from the European Hematology Association. He owns four brands/patents named “Kökten Çözüm (Deep Solution), Telehematoloji (Telehematology), Hemaferez (Hemapheresis), Kanser Kök Hücresi (Cancer Stem Cell)”. He is currently the President of the Ankara Medical Association. Prof. Dr. Osman İlhan, who served at Ankara University Faculty of Medicine for 50 years, began working at Özel Koru Ankara Hospital as of January 1, 2023.
His medical interests include:
Hematopoietic Stem Cell Transplantation (Autologous, Allogeneic)
Acute Leukemia
Chronic Leukemia Treatments
Hodgkin Lymphoma
Non-Hodgkin Lymphoma Treatments
Multiple Myeloma Treatments, MDS
Aplastic Anemia
ITP
TTP Treatments
Hypercoagulability
Hereditary Thrombophilia Treatments
Therapeutic Apheresis
Photopheresis
Geriatric Hematology Diseases.
Mehr lesenProf. Dr. Osman İLHAN graduated from Ankara University Faculty of Medicine in 1978. After completing his internal medicine residency at the same faculty in 1982, he served as a senior resident at the GATA Hematology Clinic during his military service. After completing his mandatory service at SSK Ulus Hospital, he returned to Ankara University Faculty of Medicine for a subspecialty. In 1990, he became an associate professor of hematology. He worked in Genoa, Italy to increase his knowledge and experience in leukemia. He was part of the team that performed the first bone marrow stem cell transplant in Turkey. In 1996, he went to the MD Anderson Cancer Center in the USA to work on "Stem Cell Mobilization, Cryopreservation, and Transplantation." In 1996, he became a professor of hematology. In 1999, he was elected as the regional president of ESFH (European Society for Hemapheresis). Dr. İlhan, who was the founder and president of the Hemapheresis Society in 2000, joined the World Apheresis Association (WAA) in 2001. He became the President of the Turkish Hematology Association in October 2001. Dr. İlhan, who is an active member of the European Hematology Association (EHA), was a member of the accreditation committee (ECAH) for education. He played a role in the accreditation of Turkish hematologists in CME credits by participating in the accreditation of congresses and courses held in Turkey as a Provider Status. He served as the founding president of the Cellular Therapy and Regenerative Medicine Association established in 2008. He became the founding president of the Geriatric Hematology Association in 2011. He is the Honorary President of the World Apheresis Congress (WAA) held in 2012. Dr. İlhan, who previously served on drug licensing and ethics committees at the Ministry of Health, has also served as the Chairman of the Photopheresis-Apheresis Commission and the Scientific Committee for Bone Marrow Transplantation, as well as the Chairman of the National Organ Tissue Cell Coordination Board, the Scientific Board of Cord Blood, and the Stem Cell Research Board. He is the founding president of the STEM CELL FOUNDATION and has played an important role in the establishment of TURKOK (Turkish Stem Cell Donor Bank). Dr. İlhan has over 300 publications in journals registered in PubMed and more than 5000 citations. He holds the Platinum CME certificate from the European Hematology Association. He owns four brands/patents named “Kökten Çözüm (Deep Solution), Telehematoloji (Telehematology), Hemaferez (Hemapheresis), Kanser Kök Hücresi (Cancer Stem Cell)”. He is currently the President of the Ankara Medical Association. Prof. Dr. Osman İlhan, who served at Ankara University Faculty of Medicine for 50 years, began working at Özel Koru Ankara Hospital as of January 1, 2023.
His medical interests include:
Hematopoietic Stem Cell Transplantation (Autologous, Allogeneic)
Acute Leukemia
Chronic Leukemia Treatments
Hodgkin Lymphoma
Non-Hodgkin Lymphoma Treatments
Multiple Myeloma Treatments, MDS
Aplastic Anemia
ITP
TTP Treatments
Hypercoagulability
Hereditary Thrombophilia Treatments
Therapeutic Apheresis
Photopheresis
Geriatric Hematology Diseases.
Sema Yılmaz was born on July 30, 1965. She received her undergraduate degree from Istanbul University Cerrahpaşa Medical Faculty and completed her medical residency training at the Department of Pediatrics at Zeynep Kamil Women's and Children's Health and Diseases Hospital. She also completed her medical subspecialty training in Pediatric Hematology/Oncology at Cukurova University. Her medical residency thesis was titled "The Relationship Between Morning First Urine Density and Nocturnal Enuresis in Children Aged 3-6 Years", and her medical subspecialty thesis was titled "Comparison of Sphingosine 1-phosphate Receptor 4 Gene Expression in Healthy Children and Neuroblastoma Patients". She started her medical career as a general practitioner. After working as a general practitioner for 4 years, she worked as a doctor researcher at Zeynep Kamil Women's and Children's Health and Diseases Training and Research Hospital for 5 years. She then served as a specialist doctor, assistant professor, and associate professor at various institutions. She worked at Houston MD Anderson, North Carolina-UNC, Boston-Harvard University in the USA. Additionally, she conducted research on cell therapies. She received the title of professor in Pediatric Hematology/Oncology at Usak Medical Faculty. She is a member of the Turkish Pediatric Oncology Group, European Association for Cancer Research (EACR), Turkish Medical Association, Turkish National Pediatrics Association, Turkish Pediatrics Association, Pediatrics Specialty Academy Association (PUADER), Turkish Immunology Association, Turkish Hematology Association, and Molecular Oncology Association (MOKAD). She currently serves her patients at Koru Hospital. Her medical interests include:
Cell therapies in childhood cancers
Cancer immunology
Investigation of genetic pathways responsible for cancer and metastasis
Pulmonary microbiota
BAL transplantation
Mehr lesenSema Yılmaz was born on July 30, 1965. She received her undergraduate degree from Istanbul University Cerrahpaşa Medical Faculty and completed her medical residency training at the Department of Pediatrics at Zeynep Kamil Women's and Children's Health and Diseases Hospital. She also completed her medical subspecialty training in Pediatric Hematology/Oncology at Cukurova University. Her medical residency thesis was titled "The Relationship Between Morning First Urine Density and Nocturnal Enuresis in Children Aged 3-6 Years", and her medical subspecialty thesis was titled "Comparison of Sphingosine 1-phosphate Receptor 4 Gene Expression in Healthy Children and Neuroblastoma Patients". She started her medical career as a general practitioner. After working as a general practitioner for 4 years, she worked as a doctor researcher at Zeynep Kamil Women's and Children's Health and Diseases Training and Research Hospital for 5 years. She then served as a specialist doctor, assistant professor, and associate professor at various institutions. She worked at Houston MD Anderson, North Carolina-UNC, Boston-Harvard University in the USA. Additionally, she conducted research on cell therapies. She received the title of professor in Pediatric Hematology/Oncology at Usak Medical Faculty. She is a member of the Turkish Pediatric Oncology Group, European Association for Cancer Research (EACR), Turkish Medical Association, Turkish National Pediatrics Association, Turkish Pediatrics Association, Pediatrics Specialty Academy Association (PUADER), Turkish Immunology Association, Turkish Hematology Association, and Molecular Oncology Association (MOKAD). She currently serves her patients at Koru Hospital. Her medical interests include:
Cell therapies in childhood cancers
Cancer immunology
Investigation of genetic pathways responsible for cancer and metastasis
Pulmonary microbiota
BAL transplantation
Dr. X ist ein medizinischer Onkologe mit über 30 Jahren Erfahrung. Er hat eine medizinische Ausbildung von der Universität Istanbul, Spezialisierung auf Innere Medizin, und eine Spezialisierung auf medizinische Onkologie vom Institut für Onkologie der Universität Istanbul. Er ist Mitglied der Medical Oncology Association, Lung Cancers Association, ESMO, ASCO und Istanbul Medical Chamber.
Mehr lesenDr. X ist ein medizinischer Onkologe mit über 30 Jahren Erfahrung. Er hat eine medizinische Ausbildung von der Universität Istanbul, Spezialisierung auf Innere Medizin, und eine Spezialisierung auf medizinische Onkologie vom Institut für Onkologie der Universität Istanbul. Er ist Mitglied der Medical Oncology Association, Lung Cancers Association, ESMO, ASCO und Istanbul Medical Chamber.
Spezialist für medizinische Onkologie mit Expertise in Lungen-, Brust-, Darm-, Magen-, Leber-, Nieren-, Bauchspeicheldrüsen-, Magen-, Prostata- und Gebärmutterkrebs. Erfahrung in Chemotherapie, Immuntherapie, Phytotherapie, Ozontherapie, hyperthermischer Chemotherapie, GIS-Krebs sowie gynäkologischem und Urogenitalkrebs. Mitglied der Turkish Oncology Group, Medical Oncology Association, Turkish Cancer Research and Warfare Association, European Society of Medical Oncology, European Society of Gynecologic Oncology und International Association for the Study of Lung Cancer.
Mehr lesenSpezialist für medizinische Onkologie mit Expertise in Lungen-, Brust-, Darm-, Magen-, Leber-, Nieren-, Bauchspeicheldrüsen-, Magen-, Prostata- und Gebärmutterkrebs. Erfahrung in Chemotherapie, Immuntherapie, Phytotherapie, Ozontherapie, hyperthermischer Chemotherapie, GIS-Krebs sowie gynäkologischem und Urogenitalkrebs. Mitglied der Turkish Oncology Group, Medical Oncology Association, Turkish Cancer Research and Warfare Association, European Society of Medical Oncology, European Society of Gynecologic Oncology und International Association for the Study of Lung Cancer.